Key Highlights

  • Shares trading up 1.54% to $7.26 in today's session.
  • Trading Volume reached 369.27 thousand shares.
  • The company reported an EPS of negative $1.11.
  • The collaboration targets a decentralized companion diagnostic for prostate cancer across more than 75 countries.

New Collaboration Targets Prostate Cancer Biomarker

SOPHiA GENETICS S.A. (NASDAQ:SOPH), a Swiss healthcare technology company known for its genomic data analysis platform, announced a collaboration with Myriad Genetics and AstraZeneca to advance a new prostate cancer-specific genomic instability score, called PrGIS. The biomarker is designed to assess chromosomal instability linked to homologous recombination deficiency in prostate cancer patients, supporting precision oncology treatment decisions.

Decentralized Testing Model Could Widen Global Access

As part of the collaboration, the company is developing its existing solid tumor testing solution into a decentralized companion diagnostic incorporating the new biomarker. The approach leverages the company's cloud-based platform, used across more than 1,000 institutions in over 75 countries, potentially expanding patient access to the biomarker beyond major markets.

Shares Recover Part of Prior Session's Decline

The stock's EPS of negative $1.11 reflects its continued Investment phase, though the company has been growing annual Revenue at a double-digit pace. Shares were trading modestly higher today on below-average volume, recovering part of a decline from the prior session that had been tied to insider stock sales pre-arranged to cover tax Withholding on vested Equity awards.

Outlook: Research Data Expected at Upcoming Oncology Conference

Additional research on the new biomarker, co-authored with AstraZeneca, is expected to be presented at a major oncology conference later this year. That data release may offer further validation of the biomarker's clinical Utility and serve as the next catalyst for the collaboration.